Strathmann wins cancer contract

Related tags Escherichia coli Non-small cell lung cancer

German contract manufacturer Strathmann Biotec has won a contract
to manufacture clinical supplies a new type of cancer treatment in
development at Sweden's Active Biotech.

But in contrast to a regular manufacturing contract, Strathmann​ will absorb some of the financial risk in the project, in return for a potential royalty stream up to a ceiling of €10 million should the project win through to market.

The product is Active Biotech​'s TTS (Tumour Targeted Superantigens) CD3, for the treatment of non-small cell lung cancer (NSCLC). This is still in the very early-stages of development, having just started a Phase I dose-escalation study in the US and Norway. However, a first generation of the product, TTS CD2, has concluded Phase IIa studies in renal and pancreatic cancer with promising results.

TTS CD3 is a biotechnology product which is produced using recombinant E. coli based expression system. The production of the product will be transferred from the present manufacturer - Sweden's Biovitrum - to Strathmann, which will undertake further process development.

The new process will be established at the company's production facility in Dengelsberg, Germany, and will reach a 1000 litre-scale production. Strathmann specialises in the production of recombinant proteins and plasmid DNA.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...